

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

	Three Months Ended March 31,	
	2025	2024
Revenue from government contract	\$ 1,637	\$ -
Operating expenses:		
Research and development	5,355	4,426
General and administrative	1,687	1,457
	<u>7,042</u>	<u>5,883</u>
Loss from operations	(5,405)	(5,883)
Interest income	47	33
Net loss	<u>\$ (5,358)</u>	<u>\$ (5,850)</u>
Net loss per common share	<u>\$ (0.45)</u>	<u>\$ (2.47)</u>
Weighted averages shares outstanding	11,954,797	2,367,050

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	March 31, 2025	December 31, 2024
Assets		
Cash and cash equivalents	\$ 7,439	\$ 5,507
Other current assets	3,173	2,428
Total current assets	<u>10,612</u>	<u>7,935</u>
Property and other assets	221	221
Total assets	<u>\$ 10,833</u>	<u>\$ 8,156</u>
Liabilities and stockholders' equity		
Total liabilities	\$ 2,935	\$ 3,107
Stockholders' equity	7,898	5,049
Total liabilities and stockholders' equity	<u>\$ 10,833</u>	<u>\$ 8,156</u>
Common shares outstanding	13,839,478	10,536,875